Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Linkoping

180 clinical trials in Linkoping, Sweden across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Linkoping at a glance
180
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

180 trials in Linkoping

Open in trial search

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Focal segmental glomerulosclerosis

Recruiting

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Type 2 diabetes mellitus+2

Recruiting

Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Cataract

Recruiting

Study of levofloxacin, ketorolac trometamol, and dexamethasone eye drops for preventing inflammation and infection after cataract surgery in adults

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Ntc S.r.l.

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Linkoping

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Groundbreaking studies focusing on atrial fibrillation prevention and treatment of chronic kidney disease with hypertension. Research includes novel therapies for stroke prevention and innovative drug combinations for metabolic conditions.

  • Stroke Prevention Trials
  • Hypertension Management
  • Metabolic Disorders

Current studies evaluate new anticoagulants and combination therapies for better patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer types, including lymphocytic leukemia, testicular cancer, and esophageal carcinoma. Studies focus on optimizing treatment sequences and exploring new therapeutic approaches.

  • Hematological Malignancies
  • Solid Tumors
  • Pediatric Oncology

Investigations include both conventional and innovative treatment strategies.

03 Neurological & Mental Health

Innovative research examining prolonged grief disorder and major depressive disorder. Studies investigate novel therapeutic approaches and hormone effects on decision-making processes.

  • Depression Treatment
  • Behavioral Studies
  • Hormone Research

Research combines pharmacological interventions with behavioral assessments.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.